RINREYA Trademark

Trademark Overview

On Wednesday, July 12, 2023, a trademark application was filed for RINREYA with the United States Patent and Trademark Office. The USPTO has given the RINREYA trademark a serial number of 98081534. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Wednesday, April 2, 2025. This trademark is owned by Takeda Pharmaceuticals International AG. The RINREYA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of seizures associated with Dravet Syndrome and Lennox-Gastaut Syndrome
rinreya

General Information

Serial Number98081534
Word MarkRINREYA
Filing DateWednesday, July 12, 2023
Status686 - PUBLISHED FOR OPPOSITION
Status DateWednesday, April 2, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 7, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of seizures associated with Dravet Syndrome and Lennox-Gastaut Syndrome

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, July 18, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTakeda Pharmaceuticals International AG
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGlattpark-Opfikon 8152
CH
Party NameTakeda Pharmaceuticals International AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGlattpark-Opfikon 8152
CH

Trademark Events

Event DateEvent Description
Saturday, July 15, 2023NEW APPLICATION ENTERED
Tuesday, July 18, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 9, 2023TEAS VOLUNTARY AMENDMENT RECEIVED
Wednesday, March 20, 2024ASSIGNED TO EXAMINER
Friday, March 22, 2024PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, March 27, 2024EXAMINERS AMENDMENT -WRITTEN
Wednesday, March 27, 2024EXAMINERS AMENDMENT E-MAILED
Wednesday, March 27, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, March 27, 2024EXAMINER'S AMENDMENT ENTERED
Thursday, March 28, 2024EXAMINER'S AMENDMENT ENTERED
Thursday, March 28, 2024EXAMINERS AMENDMENT -WRITTEN
Thursday, March 28, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, March 28, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, April 17, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, March 29, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 7, 2024PUBLISHED FOR OPPOSITION
Tuesday, May 7, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, December 30, 2024SOU TEAS EXTENSION RECEIVED
Monday, December 30, 2024SOU EXTENSION 1 FILED
Friday, May 10, 2024NOTICE OF ALLOWANCE CANCELLED
Friday, May 10, 2024TEAS DELETE 1(B) BASIS RECEIVED
Tuesday, July 2, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 31, 2024SOU EXTENSION 1 GRANTED
Thursday, March 27, 20251(B) BASIS DELETED; PROCEED TO REGISTRATION
Thursday, March 27, 2025ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Wednesday, April 2, 2025ELECTRONIC RECORD REVIEW COMPLETE

Related Keywords

rinreya syndrome lennox gastaut dravet associated preparations treatment seizures pharmaceutical